Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (DE:RV7)
FRANKFURT:RV7
RV7 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€35.18 - €58.18
Previous CloseN/A
Volume0.00
Average Volume (3M)72.00
Market Cap
$6.95B
Enterprise Value€8.29B
Total Cash (Recent Filing)$115.85M
Total Debt (Recent Filing)$1.51B
Price to Earnings (P/E)17.7
Beta0.67
Next Earnings
May 13, 2025EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.17
Shares Outstanding123,153,000
10 Day Avg. Volume95
30 Day Avg. Volume72
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)N/A
Price to Sales (P/S)7.45
Price to Cash Flow (P/CF)10.60
P/FCF Ratio10.60
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.68
Enterprise Value/Ebitda12.82
Forecast
1Y Price Target
€60.71Price Target Upside7.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Patent Defense SuccessSuccessfully defending its patents could lead to potential licensing revenues from Merck, bolstering its financial position and potentially implying additional avenues of revenues from other drugs where companies are looking to develop injectable versions.
Royalty OpportunitiesIf Merck owes Halozyme royalties on KEYTRUDA, this additional royalty revenue stream could be potentially even more important than that from the subcutaneous DARZALEX platform.
Bears Say
Patent Dispute RiskIf Merck's challenge prevails, Halozyme might lose out on potential income and therefore raise concerns over the validity/defensibility of HALO's subQ co-formulation patents.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.11% Insiders
31.56% Mutual Funds
23.75% Other Institutional Investors
12.40% Public Companies and
Individual Investors
RV7 FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was €35.18 and its highest was €58.18 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Halozyme Therapeutics’s market cap is $6.95B.
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 61 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Feb 18, 2025. The company reported €1.206 earnings per share for the quarter, beating the consensus estimate of €1.109 by €0.098.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is 0.88.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 123,153,000 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of €1.206 in its last earnings report, beating expectations of €1.109. Following the earnings report the stock price went up 0.906%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Currently, no hedge funds are holding shares in DE:RV7
---
Halozyme Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€60.71 (7.84% Upside)
€60.71 (7.84% Upside)
Blogger Sentiment
Bullish
DE:RV7 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.14%
12-Months-Change
Fundamentals
Return on Equity
198.42%
Trailing 12-Months
Asset Growth
24.84%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
RV7 Company Deck
---
RV7 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with record-breaking revenue, strong growth in key products, and an optimistic outlook for 2025 and beyond. While there were some setbacks, such as the delay in Amivantamab subcutaneous approval and temporary royalty rate impacts, these were overshadowed by the overall strong financial performance and strategic achievements.Read More>---
RV7 Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
---
RV7 Stock 12 Month Forecast
Average Price Target
€60.71
▲(7.84% Upside)
Technical Analysis
Best Analysts Covering RV7
1 Year
1 Year Success Rate
19/20 ratings generated profit
1 Year Average Return
+27.37%
reiterated a buy rating 9 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +27.37% per trade.
---